Literature DB >> 4597119

Response to rimiterol and salbutamol aerosols administered by intermittent positive-pressure ventilation.

N J Cooke, J A Kerr, R F Willey, M V Hoare, I W Grant, G K Cromptom.   

Abstract

The bronchodilator and cardiac effects produced by aerosols of 0.5% salbutamol and 0.5% and 1% rimiterol administered for three minutes in 40% oxygen by intermittent positive-pressure ventilation (I.P.P.V.) were compared in 15 asthmatic patients. Salbutamol and both the concentrations of rimiterol were equipotent in peak bronchodilator effect, but salbutamol had a significantly longer duration of bronchodilator action. There was significantly less increase in heart rate after rimiterol than after salbutamol. Aerosols of 0.5% rimiterol, 0.5% salbutamol, and saline were administered by I.P.P.V. to 10 normal volunteers. There was no difference between the mean heart rates after 0.5% rimiterol and saline but a highly significant increase in mean heart rate was observed after 0.5% salbutamol. It was concluded that 0.5% rimiterol was an effective short-acting bronchodilator drug with little or no cardiac beta(1)-adrenergic activity when administered for three minutes by I.P.P.V. in 40% oxygen.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4597119      PMCID: PMC1610528          DOI: 10.1136/bmj.2.5913.250

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  The comparative pharmacology of WG253 (rimiterol hydrobromide), a new bronchodilator.

Authors:  I Carney; M J Daly; J E Lightowler; R W Pickering
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-12

2.  Antagonism of acetylcholine-induced bronchospasm by WG 253, a new sympathomimetic amine.

Authors:  P Turner; J P Griffin
Journal:  J Pharm Pharmacol       Date:  1971-08       Impact factor: 3.765

3.  A comparison of the effects of isoprenaline, WG 253 and salbutamol on the tension and rate of rabbit isolated atria.

Authors:  J L Laity
Journal:  J Pharm Pharmacol       Date:  1971-08       Impact factor: 3.765

4.  A comparison of isoprenaline, salbutamol, and rimiterol inhalation on skin temperature, heart rate, and respiration in man.

Authors:  E M Phillips; M Woolnough; V M Marinova; P Turner
Journal:  J Clin Pharmacol New Drugs       Date:  1972-04

5.  The effect of a new adrenergic beta 2 -receptor-stimulating agent (rimiterol, R798) in patients with chronic obstructive lung disease.

Authors:  N Svedmyr; R Malmberg; G Thiringer
Journal:  Scand J Respir Dis       Date:  1972

6.  The relative potency of some -adrenoreceptor agonists on isolated human vein.

Authors:  K A Gailer; P A Hornsey; P Turner
Journal:  Eur J Pharmacol       Date:  1971-10       Impact factor: 4.432

7.  Clinical assessment of bronchodilator drugs delivered by aerosol.

Authors:  G M Shenfield; J W Paterson
Journal:  Thorax       Date:  1973-03       Impact factor: 9.139

8.  Response of asthmatics to isoprenaline and salbutamol aerosols administered by intermittent positive-pressure ventilation.

Authors:  Y F Choo-Kang; S S Parker; I W Grant
Journal:  Br Med J       Date:  1970-11-21
  8 in total
  7 in total

Review 1.  Rimiterol: a review of its pharmacological properties and therapeutic efficacy in asthma.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-08       Impact factor: 9.546

2.  Intravenous treatment with rimiterol and salbutamol in asthma.

Authors:  G E Marlin; P Turner
Journal:  Br Med J       Date:  1975-06-28

3.  The acute effects of the administration of rimiterol aerosol in asthmatic children.

Authors:  M I Blackhall; B Macartney; S R O'Donnell
Journal:  Br J Clin Pharmacol       Date:  1978-07       Impact factor: 4.335

4.  Effects of selective alpha 1-, alpha 2-, beta 1-and beta 2-adrenoceptor stimulation on potentials and contractions in the rabbit heart.

Authors:  I D Dukes; E M Vaughan Williams
Journal:  J Physiol       Date:  1984-10       Impact factor: 5.182

5.  Evaluation of tolerance after continuous and prolonged oral administration of salbutamol to asthmatic patients.

Authors:  S P Bhatia; H J Davies
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

6.  Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man.

Authors:  G E Marlin; P Turner
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

7.  A new bronchodilator, rimiterol hydrobromide (R 798): An open study of the bronchodilator, cardiovascular and arterial oxygen changes in asthmatic patients.

Authors:  W D Linehan
Journal:  Ir J Med Sci       Date:  1975-12       Impact factor: 1.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.